Toward harmonized phenotyping of human myeloid-derived suppressor cells by flow cytometry: results from an interim study
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
There is an increasing interest for monitoring circulating myeloid-derived suppressor cells (MDSCs) in cancer patients, but there are also divergences in their phenotypic definition. To overcome this obstacle, the Cancer Immunoguiding Program under the umbrella of the Association of Cancer Immunotherapy is coordinating a proficiency panel program that aims at harmonizing MDSC phenotyping. After a consultation period, a two-stage approach was designed to harmonize MDSC phenotype. In the first step, an international consortium of 23 laboratories immunophenotyped 10 putative MDSC subsets on pretested, peripheral blood mononuclear cells of healthy donors to assess the level of concordance and define robust marker combinations for the identification of circulating MDSCs. At this stage, no mandatory requirements to standardize reagents or protocols were introduced. Data analysis revealed a small intra-laboratory, but very high inter-laboratory variance for all MDSC subsets, especially for the granulocytic subsets. In particular, the use of a dead-cell marker altered significantly the reported percentage of granulocytic MDSCs, confirming that these cells are especially sensitive to cryopreservation and/or thawing. Importantly, the gating strategy was heterogeneous and associated with high inter-center variance. Overall, our results document the high variability in MDSC phenotyping in the multicenter setting if no harmonization/standardization measures are applied. Although the observed variability depended on a number of identified parameters, the main parameter associated with variation was the gating strategy. Based on these findings, we propose further efforts to harmonize marker combinations and gating parameters to identify strategies for a robust enumeration of MDSC subsets.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544 · cited 1×
“Myeloid-derived suppressor cells (MDSCs) are a heterogeneous group of myeloid cells at different stages of differentiation that are often expanded in cancer patients and capable to suppress immune responses [1].”
BackgroundSelf-citation
Cited by
Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards
Bronte, V., Brandau, S., Chen, S.-H., Colombo, M. P., Frey, A. B., Greten, T. F., Mandruzzato, S., Murray, P. J., Ochoa, A., Ostrand-Rosenberg, S., et al. (2016) · Nature Communications · doi:10.1038/ncomms12150 · Cited by 2,751
Self-citationMyeloid-Derived Suppressor Cells
Gabrilovich, D. I. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0297 · Cited by 1,882
Myeloid-derived suppressor cells coming of age
Veglia, F., Perego, M., & Gabrilovich, D. (2018) · Nature Immunology · doi:10.1038/s41590-017-0022-x · Cited by 1,767
Neutrophil: A Cell with Many Roles in Inflammation or Several Cell Types?
Rosales, C. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.00113 · Cited by 1,334
“The immature population is also called granulocytic myeloid derived suppressor cells (G-MDSC). but an international effort continues to find better ways for identification of these cells by flow cytometry (Mandruzzato et al., 2016).”
BackgroundCondamine, T., Dominguez, G. A., Youn, J.-I., Kossenkov, A. V., Mony, S., Alicea-Torres, K., Tcyganov, E., Hashimoto, A., Nefedova, Y., Lin, C., et al. (2016) · Science Immunology · doi:10.1126/sciimmunol.aaf8943 · Cited by 789
Neutrophil plasticity in the tumor microenvironment
Giese, M. A., Hind, L. E., & Huttenlocher, A. (2019) · Blood · doi:10.1182/blood-2018-11-844548 · Cited by 783
MDSC: Markers, development, states, and unaddressed complexity
Hegde, S., Leader, A. M., & Merad, M. (2021) · Immunity · doi:10.1016/j.immuni.2021.04.004 · Cited by 669
Ostrand-Rosenberg, S., & Fenselau, C. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1701019 · Cited by 509
“An international consortium of 23 laboratories has also been organized to test human MDSC with the goal of harmonizing staining and gating procedures for analysis of human MDSC (16).”
BackgroundNeutrophils at the crossroads of innate and adaptive immunity
Rosales, C. (2020) · Journal of Leukocyte Biology · doi:10.1002/jlb.4mir0220-574rr · Cited by 372
Neutrophil Degranulation, Plasticity, and Cancer Metastasis
Mollinedo, F. (2019) · Trends in Immunology · doi:10.1016/j.it.2019.01.006 · Cited by 353
Yang, L., Chu, Z., Liu, M., Zou, Q., Li, J., Liu, Q., Wang, Y., Wang, T., Xiang, J., & Wang, B. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01453-1 · Cited by 352
Neutrophils and PMN-MDSC: Their biological role and interaction with stromal cells
Zhou, J., Nefedova, Y., Lei, A., & Gabrilovich, D. (2018) · Seminars in Immunology · doi:10.1016/j.smim.2017.12.004 · Cited by 339
De Cicco, P., Ercolano, G., & Ianaro, A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01680 · Cited by 332
Human neutrophils: Their role in cancer and relation to myeloid-derived suppressor cells
Moses, K., & Brandau, S. (2016) · Seminars in Immunology · doi:10.1016/j.smim.2016.03.018 · Cited by 305
Self-citationHuman neutrophils in the saga of cellular heterogeneity: insights and open questions
Scapini, P., Marini, O., Tecchio, C., & Cassatella, M. A. (2016) · Immunological Reviews · doi:10.1111/imr.12448 · Cited by 274
Tumor-derived exosomes, myeloid-derived suppressor cells, and tumor microenvironment
Tian, X., Shen, H., Li, Z., Wang, T., & Wang, S. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0772-z · Cited by 264
Expansion of myeloid-derived suppressor cells in patients with severe coronavirus disease (COVID-19)
Agrati, C., Sacchi, A., Bordoni, V., Cimini, E., Notari, S., Grassi, G., Casetti, R., Tartaglia, E., Lalle, E., D’Abramo, A., et al. (2020) · Cell Death & Differentiation · doi:10.1038/s41418-020-0572-6 · Cited by 229
Cancer associated fibroblasts in cancer development and therapy
Jia, H., Chen, X., Zhang, L., & Chen, M. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01688-0 · Cited by 224
Bruno, A., Mortara, L., Baci, D., Noonan, D. M., & Albini, A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00771 · Cited by 215
“In humans, PMN-MDSCs are identified as CD11bCD14CD15 or CD11bCD14CD66b, and M-MDSCs as CD11b+CD14+HLA-DR−/loCD15− (20, 41).”
BackgroundTrovato, R., Fiore, A., Sartori, S., Canè, S., Giugno, R., Cascione, L., Paiella, S., Salvia, R., De Sanctis, F., Poffe, O., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0734-6 · Cited by 189
“subsets in the peripheral blood, following recently published guidelines [25].”
BackgroundSelf-citationAzzaoui, I., Uhel, F., Rossille, D., Pangault, C., Dulong, J., Le Priol, J., Lamy, T., Houot, R., Le Gouill, S., Cartron, G., et al. (2016) · Blood · doi:10.1182/blood-2015-08-662783 · Cited by 168
“Because there is no specific lineage marker, MDSC definitions are divergent, as such we explored by flow cytometry various panels on the first 15 patients: G-MDSC1 (LinHLA-DRCD33CD11b), G-MDSC2 (LinHLA-DRCD33CD11bCD34), G-MDSC3 (LinCD123HLA-DRCD33CD11b), G-MDSC4 (SSCCD66b) and also: M-MDSC1 (CD14HLA-DR), M-MDSC2(CD14C…”
Background
Metadata
- Authors
- Mandruzzato, S., Brandau, S., Britten, C. M., Bronte, V., Damuzzo, V., Gouttefangeas, C., Maurer, D., Ottensmeier, C., van der Burg, S. H., Welters, M. J. P., & Walter, S.
- Venue
- Cancer Immunology, Immunotherapy
- Published
- 2016-01-04
- Volume
- 65
- Issue
- 2
- Pages
- 161-169
- ISSN
- 0340-7004 (ISSN-L)
- 1432-0851
- OpenAlex
- W2230023079
- Cited by
- 202
- References
- 1
- FWCI
- 13.29
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.